We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

ISR Immune System Regulation Holding AB (publ) (ISR) NPV

Sell:8.92 SEK Buy:8.93 SEK Change: 0.25 SEK (2.73%)
Market closed |  Prices as at close on 22 October 2021 | Switch to live prices |
Sell:8.92 SEK
Buy:8.93 SEK
Change: 0.25 SEK (2.73%)
Deal now Deal for just £11.95 per trade in a Fund and Share Account
Market closed |  Prices as at close on 22 October 2021 | Switch to live prices |
Sell:8.92 SEK
Buy:8.93 SEK
Change: 0.25 SEK (2.73%)
Market closed |  Prices as at close on 22 October 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ISR Immune System Regulation Holding AB (publ) is a Sweden-based research company within the area of immunotherapy. The Company is focused the development of drug therapies for viral infections, in particular human immunodeficiency virus (HIV). The Company's product candidate, ISR048, is undergoing phase II of clinical trials for HIV indications. It provides a resistance profile, which does not require co-dosing with a boosting agent. A second generation anti-HIV drug candidate, ISR049, is in preclinical development. The Company's another drug candidate in development, ISR050, shows immunostimulatory properties that are being explored in vitro and in animal models of chronic infections, such as tuberculosis.

Contact details

Address:
Rorstrandsgatan 58
STOCKHOLM
113 40
Sweden
Telephone:
+ ()
Website:
israb.se

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ISR
ISIN:
SE0008212195
Market cap:
559.32 million SEK
Shares in issue:
60.99 million
Sector:
Biotechnology
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Anders Milton
    Chairman of the Board
  • Ola Winqvist
    Chief Executive Officer
  • Gunnar Modalen
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.